Arena Pharmaceuticals, Inc. Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results

Published: Mar 04, 2013

SAN DIEGO, March 4, 2013 -- /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reviewed financial results for the fourth quarter and full year ended December 31, 2012.

"2012 was a momentous year for Arena with the FDA approval of our first drug, BELVIQ," said Jack Lief, Arena's President and Chief Executive Officer. "It is a time of great pride, with BELVIQ representing the first of what we expect will be many novel treatments resulting from our validated research and development approach."

Back to news